The role of 1,25-dihydroxyvitamin D 3 (1,25-(OH)2 D 3 ) as a regulator of cell growth and differentiation is well recognized. Currently, 1,25-(OH)2 D 3 and vitamin D analogs are being evaluated for their therapeutic potential in the treatment of hyperproliferative disorders like cancer. In the present review, we will discuss several processes that might be involved in 1,25-(OH)2 D 3 - and vitamin D analog-mediated suppression of cancer cell growth. The effects on tumor cell proliferation, differentiation, apoptosis, angiogenesis, metastases, and parathyroid hormone-related peptide secretion will be highlighted. In addition, combination therapy with other tumor effective drugs will be addressed. Furtermore, we will focus on the potential drawbacks and the possible side effects of vitamin D compounds in the treatment of cancer.
Keywords: Anti Tumor, 1 25 Dihydroxyvitamin D3, Vitamin D Analogs, Cancer, Breast Carcinoma, Myeloid leukemia, Cervical Carcinoma, Osteosarcoma, Colon carcinoma, Ovarian carcinoma, Colorectal carcinoma/kwd, >, Pancreatic carcinoma, Fibrosarcoma, Pituitary Adenoma, Gall Bladder carcinoma, Prostate carcinoma, Intestine carcinoma, Renal cell carcinoma, Lung carcinoma, Squamous cell carcinoma, Lymphocytic leukemia, Transitional bladder carcinoma, Melanoma, Thyroid carcinoma, Medullary thyroid carcinoma, Uterine carcinosarcoma, Reduced angiogenesis, Tumor suppression, Reduction of metastases, Cell proliferation, Apoptosis, Cell differentiation, Angiogenesis, Parathyroid hormone related peptide PTH rP, Metasaes, Growth factor, Osteosarcoma human, Prostate human, Melanoma human, erythroleukemia cell line K 562, Parathyroid Hormone Related Peptide Secretion, Metastasis, cadherins fibronectin VCAM 1, Vitamin D Resistance, 22 Oxo 1 25 dihydroxyvitamin D3, Transforming growth factor
Rights & PermissionsPrintExport